1.郑州大学第一附属医院, a. 药学部; b. 内科门诊; c. 体检科; d. 口腔科,郑州 450000; 2.沈阳药科大学, 沈阳 110000
Action Mechanism of Dandeng Tongnao Capsules in the Treatment of Cerebral Infarction Based on “Component-Target-Pathway”
SHI Ying-ying1a, ZUO Li-hua1a, ZHOU Lin1a, LIU Fang-fang1b, LI Zhuo-lun1a, JIA Qing-quan2, XUE Peng1c, ZHAO Hong-yu1d, SUN Zhi1a*, ZHANG Xiao-jian1a*
1a. Department of Pharmacy; 1b. Department of Internal Medical Clinic; 1c. Department of Physical Examination; 1d. Department of Stomatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China; 2. Shenyang Pharmaceutical University, Shenyang 110000, China
Abstract：OBJECTIVE To investigate the “multi-components, multi-targets, and multi-pathways” mechanism of Dandeng Tongnao Capsules (DDTN) for the treatment of cerebral infarction (CI) using network pharmacology. METHODS The chemical components in DDTN were obtained from multiple databases and literature mining. The potential active components were screened by taking oral bioavailability (OB) ≥30% and drug-likeness (DL) ≥0.18 as indicators and the targets were predicted. The targets of CI were searched and compared with the predicted component targets. Then, the protein-protein interaction (PPI) networks of component targets and disease-related targets were constructed and integrated to screen the key targets of DDTN against CI. Finally, the GO enrichment analysis and KEGG pathway annotation analysis of key targets were conducted through the DAVID database. RESULTS Sixty-seven potential active components of DDTN were screened out, such as tanshinone IIA, formononetin, luteolin and et al, which could directly act on 25 targets for the treatment of CI, such as BCL2, MMP9, TNF and et al. And a total of 425 key targets were identified by PPI integration analysis, involving 145 biological process, 49 cellular components, 57 molecular functions and 24 regulatory pathways (P<0.05, FDR<0.05),which indicated that DDTN might have a role in treating CI by regulating some biological processes including nuclear-transcribed mRNA catabolic process nonsense-mediated decay, SRP-dependent cotranslational protein targeting to membrane and regulation of gene expression epigenetic, and some molecular function, such as RNA binding, protein binding, and enzyme binding. The mechanisms might be related to multiple regulatory pathways such as signal transduction, cellular processes, genetic information processing, and organismal systems. CONCLUSION The anti-cerebral infarction effect of DDTN shows the characteristics of traditional Chinese medicine, ie, multi-components, multi-targets, and multi-pathways. This research provides a scientific basis for further revealing the mechanism of the DDTN for the treatment of cerebral infarction.
RANDOLPH S A. Ischemic stroke [J]. Workplace Health Saf, 2016, 64(9):444.
[3]
CHAI G F, ZHANG Q P. Clinical research progress on treatment of ischemic stroke with Huoxue Huayu Method [J]. Clin J Tradit Chin Med (中医药临床杂志), 2018, 30(8):1397-1400.
[4]
COMMITTEE of NEUROLOGY, Chinese society of integrated traditional and western medicine. Guidelines for diagnosis and treatment of cerebral infarction in China (2017) [J]. Chin J Integr Tradit West Med(中国中西医结合杂志), 2018, 38(2): 136-144.
[5]
WU B H, ZHANG X G, HONG D S, et al. Simultaneous determination of eight active components in the traditional Chinese Medicine Dan Deng Tong Nao capsules by HPLC-MS/MS [J]. Planta Med, 2014, 80(6): 517-522.
[6]
LV X J, SUN Z, WANG P L, et al. Chemical profiling and quantification of Dan-Deng-Tong-Nao-capsule using ultra high performance liquid chromatography coupled with high resolution hybrid quadruple-orbitrap mass spectrometry [J]. J Pharm Biomed Anal, 2018, 148:189-204.
[7]
YUAN H D, MA Q Q, CUI H Y, et al. How can synergism of traditional medicines benefit from network pharmacology? [J]. Molecules, 2017, 22(7):1135.
[8]
RU J L, LI P, WANG J N, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines [J]. J Cheminform, 2014, 6:13.
[9]
XU X, ZHANG W, HUANG C, et al. A novel chemometric method for the prediction of human oral bioavailability [J]. Int J Mol Sci, 2012, 13(6): 6964-6982.
[10]
LUO Y X, WANG Q, ZHANG Y B, et al. A systems pharmacology approach to decipher the mechanism of Danggui-Shaoyao-San decoction for the treatment of neurodegenerative diseases [J]. J Ethnopharmacol, 2016, 178: 66-81.
[11]
KOH P O. Ferulic acid attenuates the down-regulation of MEK/ERK/p90RSK signaling pathway in focal cerebral ischemic injury [J]. Neurosci Lett, 2015, 588:18-23.
[12]
CHIEN M Y, CHUANG C H, CHERN C M, et al. Salvianolic acid A alleviates ischemic brain injury through the inhibition of inflammation and apoptosis and the promotion of neurogenesis in mice [J]. Free Radic Biol Med, 2016, 99:508-519.
[13]
SONG J, ZHANG W, WANG J, et al. Inhibition of FOXO3a/BIM signaling pathway contributes to the protective effect of salvianolic acid A against cerebral ischemia/reperfusion injury [J]. Acta Pharm Sin B(药学学报英文版), 2019, 9(3):505-515.
[14]
HOU Y H, HOU Y, HE S Y, et al. The merged basins of signal transduction pathways in spatiotemporal cell biology [J]. J Cell Physiol, 2014, 229(3):287-291.
[15]
SUN J, NAN G X. The mitogen-activated protein kinase (MAPK) signaling pathway as a discovery target in stroke [J]. J Mol Neurosci, 2016, 59(1):90-98.
[16]
ZHAO L, LIU X, LIANG J, et al. Phosphorylation of p38 MAPK mediates hypoxic preconditionin g-induced neuroprotection against cerebral ischemic injury via mitochondria translocation of Bcl-xL in mice [J]. Brain Res, 2013, 1503:78-88.
[17]
WANG C M, WEI Z J, JIANG G H, et al. Neuroprotective mechanisms of miR-124 activating PI3K/Akt signaling pathway in ischemic stroke [J]. Exp Ther Med, 2017, 13(6):3315-3318.
[18]
ZHANG Q Z, GUO Y D, LI H M, et al. Protection against cerebral infarction by withaferin A involves inhibition of neuronal apoptosis, activation of PI3K/Akt signaling pathway, and reduced intimal hyperplasia via inhibition of VSMC migration and matrix metalloproteinases [J]. Adv Med Sci, 2017, 62(1):186-192.
[19]
XU X, CHUA C C, GAO J, et al. Neuroprotective effect of humanin on cerebral ischemia/reperfusion injury is mediated by a PI3K/Akt pathway [J]. Brain Res, 2008, 1227:12-18.
[20]
LIANG Z, CHI Y J, LIN G Q, et al. MiRNA-26a promotes angiogenesis in a rat model of cerebral infarction via PI3K/AKT and MAPK/ERK pathway [J]. Eur Rev Med Pharmacol Sci, 2018, 22(11):3485-3492.
[21]
BROUGHTON B R, REUTENS D C, SOBEY C G. Apoptotic mechanisms after cerebral ischemia [J]. Stroke, 2009, 40(5):e331-9.
[22]
OUYANG Y B, GIGGARD R G. MicroRNAs affect BCL-2 family proteins in the setting of cerebral ischemia [J]. Neurochem Int, 2014, 77:2-8.
[23]
LING W J. Identification of ischemic stroke long non-coding RNA and mRNA expression profile based on microarray [D]. Nanning:Guangxi Medical University, 2017.
[24]
SUN J, NAN G. The mitogen-activated protein kinase (MAPK) signaling pathway as a discovery target in stroke [J]. J Mol Neurosci, 2016, 59:90-98.
[25]
ZHOU L, ZHANG J, WANG C, et al. Tanshinone inhibits neuronal cell apoptosis and inflammatory response in cerebral infarction rat model [J]. Int J Immunopathol Pharmacol, 2017, 30(2):123-129.
[26]
ZHOU L, BONDY S C, JIAN L, et al. Tanshinone IIA attenuates the cerebral ischemic injury-induced increase in levels of GFAP and of caspases-3 and-8 [J]. Neuroscience, 2015, 288:105-111.
[27]
CHEN Y, WU X, YU S, et al. Neuroprotective capabilities of tanshinone ⅡA against cerebral ischemia/reperfusion injury via anti-apoptotic pathway in rats[J]. Biol Pharm Bull, 2012, 35(2):164-170.
[28]
QIAO H, DONG L, ZHANG X, et al. Protective effect of luteolin in experimental ischemic stroke: upregulated SOD1, CAT, Bcl-2 and claudin-5, down-regulated MDA and Bax expression[J]. Neurochem Res, 2012, 37(9):2014-2024.
[29]
QIAO H, ZHANG X, ZHU C, et al. Luteolin downregulates TLR4, TLR5, NF-κB and p-p38MAPK expression, upregulates the p-ERK expression, and protects rat brains against focal ischemia[J]. Brain Res, 2012, 1448:71-81.
[30]
CHENG C Y, TANG N Y, KAO S T, et al. Ferulic acid administered at various time points protects against cerebral infarction by activating p38 MAPK/p90RSK/CREB/Bcl-2 anti-apoptotic signaling in the subacute phase of cerebral ischemia-reperfusion injury in rats [J]. PLoS One, 2016, 11(5):e0155748.
[31]
LIANG K, YE Y, WANG Y, et al. Formononetin mediates neuroprotection against cerebral ischemia/reperfusion in rats via downregulation of the Bax/Bcl-2 ratio and upregulation PI3K/Akt signaling pathway[J]. J Neurol Sci, 2014, 344(1-2):100-104.
2021, Vol. 56 
